BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. Biomolecules 2020;10:E1061. [PMID: 32708698 DOI: 10.3390/biom10071061] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Yoon JY, Seo SU, Woo SM, Kwon TK. USP41 Enhances Epithelial-Mesenchymal Transition of Breast Cancer Cells through Snail Stabilization. Int J Mol Sci 2023;24:1693. [PMID: 36675208 DOI: 10.3390/ijms24021693] [Reference Citation Analysis]
2 Wang Y, Yan K, Guo Y, Lu Y, Su H, Li H. IP-score correlated to endogenous tumour antigen peptide processing: A candidate clinical response score algorithm of immune checkpoint inhibitors therapy in multiple cohorts. Front Immunol 2022;13:1085491. [PMID: 36700205 DOI: 10.3389/fimmu.2022.1085491] [Reference Citation Analysis]
3 Tao S, Liang S, Zeng T, Yin D. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Front Immunol 2022;13:1043667. [PMID: 36685594 DOI: 10.3389/fimmu.2022.1043667] [Reference Citation Analysis]
4 Arakelyan J, Rusanov DA, Chang MR, Asaturova AV, Kireeva GS, Alshehri M, Ang WH, Babak MV. Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II. Coordination Chemistry Reviews 2023;475:214899. [DOI: 10.1016/j.ccr.2022.214899] [Reference Citation Analysis]
5 Poniewierska-Baran A, Słuczanowska-Głąbowska S, Małkowska P, Sierawska O, Zadroga Ł, Pawlik A, Niedźwiedzka-Rystwej P. Role of miRNA in Melanoma Development and Progression. Int J Mol Sci 2022;24. [PMID: 36613640 DOI: 10.3390/ijms24010201] [Reference Citation Analysis]
6 Shetty VV, Kellarai A. Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. JCO Glob Oncol 2022;8:e2200118. [PMID: 36198133 DOI: 10.1200/GO.22.00118] [Reference Citation Analysis]
7 Negishi T, Nakagawa T, Nishiyama N, Kitamura H, Okajima E, Furubayashi N, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Nakamura M. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Jpn J Clin Oncol 2022:hyac144. [PMID: 36093731 DOI: 10.1093/jjco/hyac144] [Reference Citation Analysis]
8 Chen Y, He J, Chen R, Wang Z, Dai Z, Liang X, Wu W, Luo P, Zhang J, Peng Y, Zhang N, Liu Z, Zhang L, Zhang H, Cheng Q. Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy. Front Immunol 2022;13:881722. [DOI: 10.3389/fimmu.2022.881722] [Reference Citation Analysis]
9 Abuhelwa AY, Bellmunt J, Kichenadasse G, Mckinnon RA, Rowland A, Sorich MJ, Hopkins AM. C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab. Front Oncol 2022;12:918993. [DOI: 10.3389/fonc.2022.918993] [Reference Citation Analysis]
10 Huang Z, Fu Y, Liu S, Mao Y, Zhang Y, Hu C, Wei R. m6A-related metabolism molecular classification with distinct prognosis and immunotherapy response in soft tissue sarcoma. Front Immunol 2022;13:895465. [DOI: 10.3389/fimmu.2022.895465] [Reference Citation Analysis]
11 Kogan AA, Topper MJ, Dellomo AJ, Stojanovic L, McLaughlin LJ, Creed TM, Eberly CL, Kingsbury TJ, Baer MR, Kessler MD, Baylin SB, Rassool FV. Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia. Proc Natl Acad Sci U S A 2022;119:e2123227119. [PMID: 35759659 DOI: 10.1073/pnas.2123227119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ren W, Ren J, Zhang N, Liu X, Deng Y, Jiang Y, Yan B, Xiao X, Yu H. CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer. Biochemical and Biophysical Research Communications 2022;613:12-8. [DOI: 10.1016/j.bbrc.2022.04.114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xu Y, Li P, Liu Y, Xin D, Lei W, Liang A, Han W, Qian W. Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials. Cancer Communications. [DOI: 10.1002/cac2.12313] [Reference Citation Analysis]
14 Nie Z, Chen M, Gao Y, Huang D, Cao H, Peng Y, Guo N, Wang F, Zhang S. Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges. Front Pharmacol 2022;13:879317. [DOI: 10.3389/fphar.2022.879317] [Reference Citation Analysis]
15 Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate 2022. [PMID: 35403746 DOI: 10.1002/pros.24351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Niebel D, Fröhlich A, Zarbl R, Fietz S, de Vos L, Vogt TJ, Dietrich J, Sirokay J, Kuster P, Saavedra G, Ramírez Valladolid S, Hoffmann F, Strieth S, Landsberg J, Dietrich D. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy. Clin Epigenetics 2022;14:50. [PMID: 35410311 DOI: 10.1186/s13148-022-01270-2] [Reference Citation Analysis]
17 Pei Y, Qian Y, Wang H, Tan L. Epigenetic Regulation of Ferroptosis-Associated Genes and Its Implication in Cancer Therapy. Front Oncol 2022;12:771870. [DOI: 10.3389/fonc.2022.771870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [DOI: 10.4251/wjgo.v14.i1.19] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Perrier A, Hainaut P, Guenoun A, Nguyen D, Lamy P, Guerber F, Troalen F, Denis JA, Boissan M. En marche vers une oncologie personnalisée : l’apport des techniques génomiques et de l’intelligence artificielle dans l’usage des biomarqueurs tumoraux circulants. Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2021.12.005] [Reference Citation Analysis]
20 Sun B, Zhao H. The bioinformatics analysis of RIOX2 gene in lung adenocarcinoma and squamous cell carcinoma. PLoS One 2021;16:e0259447. [PMID: 34855761 DOI: 10.1371/journal.pone.0259447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Long Q, Huang C, Huang J, Meng Q, Cheng Y, Li Y, He L, Chen M, Zhang C, Wang X, Zhu W, Peng J, Shi D, Zheng F, Dong P, Deng W. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.11.016] [Reference Citation Analysis]
22 Banerjee R, Smith J, Eccles MR, Weeks RJ, Chatterjee A. Epigenetic basis and targeting of cancer metastasis. Trends in Cancer 2021. [DOI: 10.1016/j.trecan.2021.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hoffmann MJ, Schulz WA. Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma. Cancers (Basel) 2021;13:6040. [PMID: 34885146 DOI: 10.3390/cancers13236040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sun H, Li X, Zhang J, Liu Y. Clinicopathological features and genomic profiles of hepatoid adenocarcinoma of the lung: Report of four cases. Pathol Res Pract 2021;229:153652. [PMID: 34826742 DOI: 10.1016/j.prp.2021.153652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Yoshie O. CCR4 as a Therapeutic Target for Cancer Immunotherapy. Cancers (Basel) 2021;13:5542. [PMID: 34771703 DOI: 10.3390/cancers13215542] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
26 Huang KC, Chiang S, Ke T, Chen T, Hu C, Yang P, Chang H, Liang J, Chen WT, Chao KSC. DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy. OncoImmunology 2021;10:1989790. [DOI: 10.1080/2162402x.2021.1989790] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Kumar S, Sarthi P, Mani I, Ashraf MU, Kang MH, Kumar V, Bae YS. Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. Cells 2021;10:2250. [PMID: 34571899 DOI: 10.3390/cells10092250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Wu Q, Berglund AE, Etame AB. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. Int J Mol Sci 2021;22:8324. [PMID: 34361090 DOI: 10.3390/ijms22158324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med 2021;9:1037. [PMID: 34277837 DOI: 10.21037/atm-20-6833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
30 Augustus E, Zwaenepoel K, Siozopoulou V, Raskin J, Jordaens S, Baggerman G, Sorber L, Roeyen G, Peeters M, Pauwels P. Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle. Cancers (Basel) 2021;13:1675. [PMID: 33918147 DOI: 10.3390/cancers13071675] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
31 Satoh H, Miyazaki K, Shiozawa T, Kagohashi K. Long-term control in a patient with metastatic lung adenocarcinoma after discontinuation of nivolumab. J Oncol Pharm Pract 2021;27:1052-3. [PMID: 33779368 DOI: 10.1177/10781552211004694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Zeng X, Zhong M, Yang Y, Wang Z, Zhu Y. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27kip1 /CDK4 axis in non-small cell lung cancer. J Cell Mol Med 2021;25:4136-47. [PMID: 33630417 DOI: 10.1111/jcmm.16383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
33 Suda K. Recent Advances in Cancer Immunotherapy. Biomolecules 2021;11:335. [PMID: 33672298 DOI: 10.3390/biom11020335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Little M. Outlook. Antibodies for Treating Cancer 2021. [DOI: 10.1007/978-3-030-72599-0_11] [Reference Citation Analysis]
35 Anichini A, Perotti VE, Sgambelluri F, Mortarini R. Immune Escape Mechanisms in Non Small Cell Lung Cancer. Cancers (Basel) 2020;12:E3605. [PMID: 33276569 DOI: 10.3390/cancers12123605] [Cited by in Crossref: 41] [Cited by in F6Publishing: 51] [Article Influence: 13.7] [Reference Citation Analysis]